Agenus Inc. (AGEN)

4.35
NASDAQ : Health Technology
Prev Close 4.21
Day Low/High 4.03 / 4.37
52 Wk Low/High 3.20 / 5.45
Avg Volume 1.09M
Exchange NASDAQ
Shares Outstanding 101.97M
Market Cap 386.45M
EPS -1.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Agenus Announces Key Leadership To Advance Combination Trials For Planned BLA Filings

Agenus Announces Key Leadership To Advance Combination Trials For Planned BLA Filings

-- Hagop Youssoufian, MD, named Senior Clinical Strategist

Agenus Receives License Fee Of $4 Million USD From Merck

Agenus Receives License Fee Of $4 Million USD From Merck

Entitled up to an additional $99 million USD in success milestones plus royalties on sales

Interesting AGEN Put And Call Options For December 15th

Investors in Agenus Inc saw new options begin trading this week, for the December 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AGEN options chain for the new December 15th contracts and identified one put and one call contract of particular interest.

It's All About the Earnings: Cramer's 'Mad Money' Recap (Monday 10/23/17)

It's All About the Earnings: Cramer's 'Mad Money' Recap (Monday 10/23/17)

A not-so-hot-day for the market, says Jim Cramer, but it pays to be optimistic about the stocks of companies that deliver good earnings numbers.

Bruno Lucidi Appointed Chief Executive Officer Of AgenTus Therapeutics, The Cell Therapy Subsidiary Of Agenus

Bruno Lucidi Appointed Chief Executive Officer Of AgenTus Therapeutics, The Cell Therapy Subsidiary Of Agenus

Bruno Lucidi, previously of Idenix, Pharmasset and BMS named AgenTus CEO

Agenus Creates New Cell Therapy Subsidiary Named AgenTus Therapeutics

Agenus Creates New Cell Therapy Subsidiary Named AgenTus Therapeutics

Bruno Lucidi, previously of Idenix, Pharmasset and BMS named AgenTus CEO

FDA Approves GSK's Shingles Vaccine With Agenus' QS-21 Stimulon® Adjuvant

FDA Approves GSK's Shingles Vaccine With Agenus' QS-21 Stimulon® Adjuvant

- SHINGRIX containing QS-21 Stimulon® demonstrates remarkable efficacy of greater than 90% in pooled studies against shingles

GSK's Shingrix Containing Agenus' QS-21 Stimulon® Adjuvant Receives Marketing Authorization From Health Canada

GSK's Shingrix Containing Agenus' QS-21 Stimulon® Adjuvant Receives Marketing Authorization From Health Canada

First approval for a vaccine enhanced with QS-21 Stimulon®

AGEN September 15th Options Begin Trading

AGEN September 15th Options Begin Trading

Investors in Agenus Inc saw new options become available today, for the September 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AGEN options chain for the new September 15th contracts and identified the following put contract of particular interest.

Market's Trading Range Loosens Up

Market's Trading Range Loosens Up

Netflix is the star as S&P, Nasdaq set records.

Agenus Stock Sees Short Interest Decline 14.4%

Agenus Stock Sees Short Interest Decline 14.4%

The most recent short interest data has been released for the 06/30/2017 settlement date, which shows a 1,600,454 share decrease in total short interest for Agenus Inc , to 9,488,666, a decrease of 14.43% since 06/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Positive Phase 3 For GSK's Shingles Vaccine Shingrix With Agenus' QS-21 Stimulon® Immune Adjuvant

-GSK to present the revaccination study results at the CDC's Advisory Meeting on patients who had previously received standard of care treatment-

First Week of February 2018 Options Trading For Agenus (AGEN)

Investors in Agenus Inc saw new options begin trading this week, for the February 2018 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

First Week Of AGEN November 17th Options Trading

Investors in Agenus Inc saw new options become available this week, for the November 17th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

TheStreet Quant Rating: D (Sell)